At the cutting edge of biomedical innovation, the 'ESPERANCE' project of 2025 brought together pioneers and visionaries to reimagine the future of drug discovery. Among the highlights of this year’s event was the thought-provoking session “Accelerating Drug Discovery: Robotic Screening on 3D Cultures for Rapid Feedback to Structure-Driven Design Before Animal Testing” featuring none other than Dr. Dimitris Kyriakou, a key scientific advisor to the VITALE project.

​

Dr. Kyriakou’s live talk not only drew a full house of experts and innovators, but also resonated across sectors, underlining a bold shift in how we approach preclinical testing, automation, and ethical biomedical research. His presentation bridged the gap between conceptual promise and tangible progress proving that early integration of robotic platforms in 3D culture screening is not just a luxury, but a necessity.

From Vision to Validation: The Impact on VITALE

The ESPERANCE project and event attendance served as a timely stage to showcase how the proposed VITALE software project ecosystem is evolving into an essential tool for Life-Science laboratories. Thanks to insights from Dr. Kyriakou’s session, the VITALE development team has doubled down on integrating real-time feedback loops between experiment and design, specifically for organoid and tissue-on-chip platforms. ​By reinforcing the principles of automation, data transparency, and structure-guided experimentation, his intervention catalyzed two concrete outcomes:

​​

1. Enhanced Model Integration: Inspired by the discussions on robotic 3D screening, VITALE will now support more modular integration of robotic workflows for sample handling, imaging, and data interpretation critical for reducing experiment cycles and avoiding unnecessary in vivo studies.

2. Accelerated AI Alignment: Dr. Kyriakou’s emphasis on feedback-driven design motivated the immediate alignment of VITALE’s AI modules to accept dynamic inputs from robotic assays, thereby refining its predictive capabilities in structure activity relationships (SAR) at the preclinical stage.

A Turning Point for Ethical Innovation

Beyond the technical refinements, ESPERANCE 2025 marked a turning point in VITALE’s narrative as a force for responsible and ethical research. By showcasing alternatives to animal testing powered by automation and AI, the event validated VITALE’s mission to enable smarter, faster, and ethically sound experimentation, while keeping scientists in full control of their data and protocols. Dr. Kyriakou’s participation didn’t just elevate the event, it positioned VITALE as a front-runner in the digitalization of biomedical Research & Development.

Looking Ahead: From ESPERANCE to Execution